See more : Artificial Life, Inc. (ALIF) Income Statement Analysis – Financial Results
Complete financial analysis of iCAD, Inc. (ICAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iCAD, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Wonderful Sky Financial Group Holdings Limited (1260.HK) Income Statement Analysis – Financial Results
- Corner Growth Acquisition Corp. (COOL) Income Statement Analysis – Financial Results
- Luoniushan Co., Ltd. (000735.SZ) Income Statement Analysis – Financial Results
- Bayer Aktiengesellschaft (BAYN.SG) Income Statement Analysis – Financial Results
- GECI INTL BSAR A (GECBT.PA) Income Statement Analysis – Financial Results
iCAD, Inc. (ICAD)
About iCAD, Inc.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.32M | 27.94M | 33.64M | 29.70M | 31.34M | 25.62M | 28.10M | 26.34M | 41.55M | 43.92M | 33.07M | 28.28M | 28.65M | 24.58M | 28.11M | 37.49M | 26.61M | 19.72M | 19.77M | 23.31M | 6.52M | 5.00M | 4.84M | 7.79M | 6.70M | 5.30M | 7.90M | 11.30M | 20.60M | 24.40M | 20.60M | 23.00M | 11.90M | 21.70M | 18.40M | 11.20M | 2.70M |
| Cost of Revenue | 2.78M | 8.13M | 9.40M | 8.34M | 7.11M | 6.19M | 9.93M | 7.82M | 12.20M | 12.70M | 9.98M | 8.24M | 8.63M | 3.15M | 4.62M | 6.18M | 5.26M | 4.29M | 4.64M | 6.53M | 2.94M | 5.16M | 3.94M | 5.27M | 4.50M | 3.40M | 4.90M | 7.10M | 12.00M | 13.50M | 11.70M | 10.40M | 6.90M | 12.10M | 12.10M | 7.60M | 7.10M |
| Gross Profit | 14.54M | 19.81M | 24.24M | 21.35M | 24.23M | 19.43M | 18.18M | 18.52M | 29.35M | 31.23M | 23.09M | 20.03M | 20.03M | 21.43M | 23.49M | 31.32M | 21.36M | 15.43M | 15.13M | 16.78M | 3.58M | -161.46K | 898.89K | 2.52M | 2.20M | 1.90M | 3.00M | 4.20M | 8.60M | 10.90M | 8.90M | 12.60M | 5.00M | 9.60M | 6.30M | 3.60M | -4.40M |
| Gross Profit Ratio | 83.94% | 70.90% | 72.07% | 71.90% | 77.30% | 75.84% | 64.68% | 70.31% | 70.63% | 71.09% | 69.81% | 70.84% | 69.90% | 87.20% | 83.56% | 83.53% | 80.25% | 78.24% | 76.55% | 71.97% | 54.88% | -3.23% | 18.59% | 32.38% | 32.84% | 35.85% | 37.97% | 37.17% | 41.75% | 44.67% | 43.20% | 54.78% | 42.02% | 44.24% | 34.24% | 32.14% | -162.96% |
| Research & Development | 5.16M | 8.59M | 9.19M | 8.11M | 9.27M | 9.45M | 9.33M | 9.52M | 9.16M | 8.16M | 7.69M | 7.77M | 10.79M | 6.60M | 7.22M | 7.12M | 4.50M | 5.26M | 4.79M | 4.83M | 2.38M | 1.63M | 751.47K | 709.60K | 800.00K | 1.10M | 1.40M | 2.40M | 2.80M | 2.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.32M | 11.23M | 10.41M | 9.12M | 7.44M | 9.12M | 7.88M | 7.68M | 8.79M | 8.04M | 6.74M | 6.97M | 10.08M | 9.92M | 7.35M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.74M | 13.69M | 15.14M | 13.31M | 13.63M | 8.69M | 10.50M | 10.18M | 12.40M | 12.47M | 10.43M | 10.71M | 13.68M | 11.49M | 11.04M | 11.96M | 10.78M | 9.23M | 8.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.06M | 24.93M | 25.54M | 22.43M | 21.08M | 17.81M | 18.38M | 17.85M | 21.19M | 20.51M | 17.17M | 17.67M | 23.76M | 21.40M | 18.39M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 5.10M | 8.00M | 7.20M | 8.80M | 9.80M | 7.70M | 7.90M | 0.00 |
| Other Expenses | 0.00 | 224.00K | 240.00K | 199.00K | 276.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| Operating Expenses | 22.23M | 33.74M | 34.98M | 30.74M | 30.62M | 27.56M | 28.16M | 28.49M | 31.99M | 30.41M | 24.86M | 25.44M | 30.39M | 28.00M | 25.61M | 26.55M | 22.46M | 21.87M | 19.89M | 17.04M | 11.66M | 9.21M | 3.44M | 4.22M | 4.40M | 4.80M | 6.10M | 9.60M | 10.80M | 9.60M | 9.30M | 8.40M | 9.50M | 11.80M | 9.50M | 8.50M | 500.00K |
| Cost & Expenses | 25.01M | 41.87M | 44.37M | 39.09M | 37.74M | 33.75M | 38.09M | 36.31M | 44.19M | 43.11M | 34.84M | 33.69M | 39.02M | 31.15M | 30.23M | 32.73M | 27.72M | 26.16M | 24.52M | 23.58M | 14.60M | 14.37M | 7.38M | 9.49M | 8.90M | 8.20M | 11.00M | 16.70M | 22.80M | 23.10M | 21.00M | 18.80M | 16.40M | 23.90M | 21.60M | 16.10M | 7.60M |
| Interest Income | 729.00K | 213.00K | 15.00K | 97.00K | 344.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | 24.00K | 73.27K | 119.10K | 106.03K | 74.15K | 102.96K | 127.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.00K | 10.00K | 141.00K | 476.00K | 784.00K | 504.00K | 124.00K | 63.00K | 650.00K | 2.64M | 3.28M | 3.42M | 419.00K | 269.00 | 9.33K | 280.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 409.00K | 521.00K | 557.00K | 578.00K | 673.00K | 708.00K | 1.49M | 2.31M | 3.35M | 3.53M | 2.43M | 2.80M | 3.17M | 1.64M | 1.92M | 1.84M | 1.70M | 1.66M | 1.63M | 1.34M | 667.89K | 389.88K | 486.14K | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| EBITDA | -6.57M | -9.50M | -10.55M | -16.52M | -12.05M | -7.31M | -12.66M | -7.67M | -28.43M | 4.34M | -1.77M | -3.12M | -34.42M | -4.58M | -80.66K | 6.71M | 598.07K | -4.67M | -3.00M | 1.07M | -7.42M | -8.98M | -2.05M | -1.07M | -1.60M | -2.20M | -1.80M | -3.20M | -200.00K | 2.90M | 900.00K | 5.40M | -3.80M | -200.00K | -1.40M | -4.30M | -4.40M |
| EBITDA Ratio | -37.91% | -47.38% | -30.20% | -54.48% | -38.45% | -30.30% | -30.16% | -29.06% | 1.76% | 9.97% | 2.04% | -9.13% | -25.02% | -19.76% | -7.55% | 17.62% | 2.25% | -24.21% | -15.79% | 4.60% | -113.73% | -179.60% | -42.49% | -13.75% | -23.88% | -41.51% | -55.70% | -28.32% | 12.14% | 11.89% | 4.37% | 23.48% | -31.93% | -0.92% | -7.61% | -38.39% | -44.44% |
| Operating Income | -7.69M | -13.93M | -10.73M | -9.39M | -6.40M | -8.13M | -14.17M | -9.97M | -30.08M | 815.00K | -1.78M | -5.41M | -37.19M | -6.57M | -2.12M | 4.77M | -1.10M | -6.44M | -4.75M | -267.22K | -8.08M | -9.37M | -2.54M | -1.70M | -2.20M | -2.90M | -3.10M | -5.40M | -2.20M | 1.30M | -400.00K | 4.20M | -4.50M | -2.20M | -3.20M | -4.90M | -4.90M |
| Operating Income Ratio | -44.40% | -49.85% | -31.90% | -31.61% | -20.41% | -31.73% | -50.42% | -37.85% | -72.39% | 1.86% | -5.37% | -19.14% | -129.81% | -26.74% | -7.55% | 12.71% | -4.15% | -32.65% | -24.05% | -1.15% | -123.98% | -187.40% | -52.54% | -21.76% | -32.84% | -54.72% | -39.24% | -47.79% | -10.68% | 5.33% | -1.94% | 18.26% | -37.82% | -10.14% | -17.39% | -43.75% | -181.48% |
| Total Other Income/Expenses | 699.00K | 164.00K | -512.00K | -8.18M | -7.11M | -845.00K | -106.00K | -53.00K | -2.35M | -1.67M | -5.71M | -3.92M | -395.00K | 348.27K | 109.77K | -174.60K | -434.73K | -199.28K | -3.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.60M | 0.00 | -2.70M | -300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.20M |
| Income Before Tax | -6.99M | -13.77M | -11.24M | -17.57M | -13.51M | -8.98M | -14.27M | -10.02M | -32.43M | -856.00K | -7.48M | -9.33M | -37.59M | -6.22M | -2.01M | 4.59M | -1.54M | -6.64M | -4.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 | -4.90M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.10M |
| Income Before Tax Ratio | -40.36% | -49.28% | -33.43% | -59.17% | -43.10% | -35.03% | -50.79% | -38.06% | -78.05% | -1.95% | -22.63% | -33.00% | -131.18% | -25.33% | -7.15% | 12.25% | -5.78% | -33.66% | -24.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6.33% | 0.00% | -23.79% | 4.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -300.00% |
| Income Tax Expense | 20.00K | -116.00K | 1.00K | 38.00K | 43.00K | 42.00K | -18.00K | 76.00K | 16.00K | 153.00K | 126.00K | 43.00K | 419.00K | 0.00 | -43.57K | 235.00K | 0.00 | 0.00 | 0.00 | 561.04K | 114.66K | 48.17K | 80.11K | 132.01K | 1.80M | 500.00K | -2.30M | 700.00K | 3.10M | 100.00K | 400.00K | 400.00K | 500.00K | 100.00K | 300.00K | 400.00K | 3.70M |
| Net Income | -4.85M | -13.66M | -11.25M | -17.61M | -13.55M | -9.02M | -14.26M | -10.10M | -32.45M | -1.01M | -7.61M | -9.37M | -37.59M | -6.22M | -1.97M | 4.36M | -1.54M | -6.64M | -4.76M | -828.26K | -8.20M | -9.42M | -2.62M | -1.83M | -4.00M | -3.40M | -800.00K | -6.10M | -5.30M | 900.00K | -800.00K | 3.80M | -5.00M | -2.30M | -3.50M | -5.30M | -8.60M |
| Net Income Ratio | -27.99% | -48.87% | -33.43% | -59.30% | -43.24% | -35.19% | -50.73% | -38.34% | -78.08% | -2.30% | -23.01% | -33.15% | -131.18% | -25.33% | -7.00% | 11.62% | -5.78% | -33.66% | -24.07% | -3.55% | -125.74% | -188.36% | -54.20% | -23.45% | -59.70% | -64.15% | -10.13% | -53.98% | -25.73% | 3.69% | -3.88% | 16.52% | -42.02% | -10.60% | -19.02% | -47.32% | -318.52% |
| EPS | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.44 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| EPS Diluted | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.40 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| Weighted Avg Shares Out | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.68M | 16.34M | 15.93M | 15.67M | 14.10M | 10.84M | 10.77M | 10.91M | 9.17M | 9.10M | 8.34M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 1.81M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
| Weighted Avg Shares Out (Dil) | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.69M | 16.34M | 15.93M | 15.69M | 14.10M | 10.84M | 10.80M | 10.91M | 9.17M | 9.10M | 8.55M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 2.00M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
Icad (ICAD) Reports Q4 Loss, Misses Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of -9.09% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End
Strategy focused on profitability by end of 2024, using current cash on hand
iCAD's Breast AI Suite Empowers Customers to Lead the Way in Support of FDA's National Breast Density Reporting Standard
iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference
7 Tantalizing Technology Stocks to Buy for Long-Term Growth
For the last two years, tech stocks have been weighed down by the Steet's worries about elevated inflation and the Fed's rate hikes in response to high inflation. But in the coming months, inflation is widely expected to drop sharply.
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
Company is exploring strategic options for its Therapy business line Company is exploring strategic options for its Therapy business line
New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists' Efficiency and Accuracy
Company's Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023 Company's Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023
7 Super Speculative Stocks That Could Make You Very Rich
Growth stocks are indisputably heating up on Wall Street. In a recent CNBC article, the financial news outlet suggested that “retail investors” are responsible for the surge.
iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI
Daniel Shea appointed as interim Chief Financial Officer
World’s First Intracranial Use of a New High-Frequency Imaging System to Directly Visualize Neurovascular Pathologies
BOSTON--(BUSINESS WIRE)--Gentuity, LLC, an advanced imaging technology firm, today announced the first human use of the Vis-MTM High-Frequency Optical Coherence Tomography (HF-OCT) imaging system and probe. This represents a significant technological advance for the field of neurointervention, making high resolution...
Software as a Medical Device Global Market Outlook 2022: Increasing Venture Capital Funding Bolsters Sector - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Software as a Medical Device: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering. In this report, the market has been segmented based on product type and geography. The report provides an overview of the software as...
Source: https://incomestatements.info
Category: Stock Reports